| Identification | Back Directory | [Name]
KVI-020 | [CAS]
1000306-34-2 | [Synonyms]
KVI-020
WYE-160020
N-[(4R)-4-(4-methoxyphenyl)-3-[2-(4-methoxyphenyl)ethyl]-2-oxoimidazolidin-1-yl]methanesulfonamide
Methanesulfonamide, N-[(4R)-4-(4-methoxyphenyl)-3-[2-(4-methoxyphenyl)ethyl]-2-oxo-1-imidazolidinyl]- | [Molecular Formula]
C20H25N3O5S | [MOL File]
1000306-34-2.mol | [Molecular Weight]
419.49 |
| Hazard Information | Back Directory | [Uses]
KVI-020 is an orally active, potent and selective blocker of the atrial potassium channel Kv1.5, with an IC50 of 480 nM. KVI-020 can inhibits hERG, with an IC50 of 15100 nM. KVI-020 is a potent antiarrhythmic agent, and can be used for atrial fibrillation (AF) research[1]. | [References]
[1] Blass BE, et al. Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia. J Med Chem. 2009 Nov 12;52(21):65 DOI:10.1021/jm901042m |
|
|